OPTIMA Trial Finds a Gene-Expression Test Can Spare Two-Thirds of High-Risk Breast Cancer Patients From Chemotherapy
The 4,429-patient Phase III OPTIMA trial found that a Prosigna ROR-guided strategy was non-inferior to standard chemotherapy in ER-positive, HER2-negative early breast cancer, letting 68% of clinically high-risk patients skip chemo.